Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and ...
Cryo-Cell International, Inc. (NYSE: CCEL) is a healthcare company specializing in the collection, processing, and cryogenic storage of umbilical cord blood and cord tissue stem cells for family use. As the pioneer in the private cord blood banking industry, Cryo-Cell has built a strong reputation for innovation and quality, serving ...Cryo-Cell International, Inc. (NYSE: CCEL) is a healthcare company specializing in the collection, processing, and cryogenic storage of umbilical cord blood and cord tissue stem cells for family use. As the pioneer in the private cord blood banking industry, Cryo-Cell has built a strong reputation for innovation and quality, serving over 500,000 parents across 87 countries since its founding in 1989 by Dan Richard. The company is headquartered in Oldsmar, Florida, and operates with a dedicated team of approximately 72 employees.
The company's primary products include cord blood and cord tissue storage services, with a focus on preserving stem cells for future medical treatments. Additionally, Cryo-Cell manufactures PrepaCyte CB processing systems, which are used to efficiently process cord blood stem cells. Beyond family banking, the company provides cold storage services to third-party pharmaceutical companies and medical institutions, leveraging its expertise in cryopreservation.
Financially, Cryo-Cell reported a market capitalization of $28.3 million as of 2023, with a stock price of $3.51. The company generates revenue primarily from storage fees and processing services, with a gross profit margin of 77.3%. Despite a negative net profit margin of -7.9% in the trailing twelve months, the company maintains a strong operating cash flow, indicating resilience in its core operations. The company pays a dividend of $0.65 per share, reflecting a commitment to returning value to shareholders.
Leadership is shared by Co-CEOs David Portnoy and Mark Portnoy, who have been guiding the company since 2011. Their strategic direction focuses on expanding market reach and enhancing service offerings. Cryo-Cell is recognized as an industry leader, with a history of pioneering innovations such as the separation and storage of stem cells from cord blood. The company's commitment to excellence has earned it the trust of healthcare professionals and families worldwide.
